A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined With Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis

This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).

Study Overview

• Status: Terminated
• Conditions: Atopic Dermatitis
• Intervention / Treatment: Other: Placebo; Drug: Tezepelumab

Detailed Description

All subjects will receive a subcutaneous (SC) dose of either investigational product or placebo as the first dose on day 1.

Subjects who are determined to be non-responders in Part A will receive tezepelumab SC every 2 weeks (Q2W) following completion of all week 16 study activities. Nonresponders are defined as those subjects who have not achieved at least a 50% improvement in Eczema Area and Severity Index (EASI) at week 16 compared to baseline (day 1).

Safety follow-up is 18 weeks after the end of treatment (EOT) visit (20 weeks after the final dose of investigational product).

• Study Type: Interventional
• Enrollment (Actual): 251
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Sydney, New South Wales, Australia, 2010
      • Holdsworth House Medical Practice
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • Veracity Clinical Research
  • Victoria
    • Carlton, Victoria, Australia, 3053
      • Skin Health Institute
    • Parkville, Victoria, Australia, 3050
      • The Royal Melbourne Hospital
  • Western Australia
    • Fremantle, Western Australia, Australia, 6160
      • Fremantle Dermatology
• Canada
  • British Columbia
    • Surrey, British Columbia, Canada, V3R 6A7
      • Doctor Chih-Ho Hong Medical Incorporated
  • Ontario
    • London, Ontario, Canada, N6H 5L5
      • DermEffects
    • Markham, Ontario, Canada, L3P 1X3
      • Lynderm Research Inc
    • Mississauga, Ontario, Canada, L5A 3V4
      • Cheema Research Incorporated
    • Newmarket, Ontario, Canada, L3Y 5G8
      • SKDS Research Incorporated
    • North York, Ontario, Canada, M3B 3S6
      • Gordon Sussman Clinical Research Incorporated
    • Ottawa, Ontario, Canada, K1H 7X3
      • JRB Research Incorporated
• Czechia
  • Brno, Czechia, 656 91
    • Fakultni nemocnice u sv Anny v Brne
  • Novy Jicin, Czechia, 741 01
    • Nemocnice Novy Jicin as
  • Ostrava-Poruba, Czechia, 708 52
    • Fakultni Nemocnice Ostrava
  • Praha 1, Czechia, 110 00
    • Sanatorium Profesora Arenbergera
  • Praha 8, Czechia, 180 81
    • Nemocnice Na Bulovce
• Estonia
  • Tallinn, Estonia, 13419
    • North Estonia Medical Centre
  • Tartu, Estonia, 50106
    • Clinical Research Centre
  • Tartu, Estonia, 50417
    • Tartu University Hospital
• Germany
  • Berlin, Germany, 10117
    • Charité Berlin
  • Göttingen, Germany, 37075
    • Universitätsmedizin Göttingen - Georg-August-Universität
  • Hannover, Germany, 30625
    • Medizinische Hochschule Hannover
• Hungary
  • Budapest, Hungary, 1036
    • Obudai Egeszsegugyi Centrum Kft
  • Budapest, Hungary, 1027
    • Csalogany Orvosi Kozpont
  • Debrecen, Hungary, 4031
    • Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz
  • Miskolc, Hungary, 3529
    • CRU Hungary Kft
  • Pecs, Hungary, 7632
    • Pécsi Tudományegyetem Klinikai Központ
  • Szeged, Hungary, 6720
    • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar
• Japan
  • Chiba
    • Sakura-shi, Chiba, Japan, 285-8741
      • Toho University Sakura Medical Center
  • Fukuoka
    • Fukuoka-shi, Fukuoka, Japan, 814-0180
      • Fukuoka University Hospital
  • Hokkaido
    • Obihiro-shi, Hokkaido, Japan, 080-0013
      • Takagi Dermatological Clinic
    • Sapporo-shi, Hokkaido, Japan, 060-0063
      • Medical Corporation Kojinkai Sapporo Skin Clinic
  • Hyogo
    • Nishinomiya-shi, Hyogo, Japan, 663-8186
      • Meiwa Hospital
  • Nagasaki
    • Nagasaki-shi, Nagasaki, Japan, 852-8501
      • Nagasaki University Hospital
  • Osaka
    • Sakai-shi, Osaka, Japan, 593-8324
      • Kume Clinic
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8603
      • Nippon Medical School Hospital
    • Chiyoda-ku, Tokyo, Japan, 102-8798
      • Japan Post Holdings Co Ltd Tokyo Teishin Hospital
    • Shinagawa-ku, Tokyo, Japan, 141-8625
      • NTT Medical Center Tokyo
    • Shinjuku-ku, Tokyo, Japan, 162-8655
      • Center Hospital of the National Center for Global Health and Medicine
  • Toyama
    • Takaoka-shi, Toyama, Japan, 933-0871
      • Shirasaki Dermatology Clinic
• Korea, Republic of
  • Seoul, Korea, Republic of, 07441
    • Hallym University Kangnam Sacred Heart Hospital
• Latvia
  • Riga, Latvia, 1001
    • Riga First Hospital
  • Riga, Latvia, 1003
    • J Kisis
  • Riga, Latvia, 1011
    • Clinic Latvian Dermatology Institute
  • Ventspils, Latvia, 3601
    • Outpatient Clinic Of Ventspils
• Poland
  • Gdansk, Poland, 80-214
    • Uniwersyteckie Centrum Kliniczne
  • Lodz, Poland, 90-242
    • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo-Akcyjna
  • Lodz, Poland, 90-436
    • Dermoklinika Centrum Medyczne Spolka cywilna M Kierstan J Narbutt A Lesiak
  • Lublin, Poland, 20-406
    • Niepubliczny Zaklad Opieki Zdrowotnej Med Laser Borzecki Spolka Jawna
  • Swidnik, Poland, 21-040
    • Tomasz Blicharski Lubelskie Centrum Diagnostyczne
  • Warszawa, Poland, 01-868
    • Centrum Medyczne Pratia Warszawa
  • Wroclaw, Poland, 50-224
    • Medicus Sp z o o
  • Wroclaw, Poland, 51-318
    • DermMedica Spzoo
• Spain
  • Madrid, Spain, 28006
    • Hospital Universitario de La Princesa
  • AndalucÃ-a
    • Sevilla, AndalucÃ-a, Spain, 41009
      • Hospital Universitario Virgen Macarena
  • Cataluña
    • Badalona, Cataluña, Spain, 08916
      • Hospital Universitari Germans Trias i Pujol
    • Barcelona, Cataluña, Spain, 08003
      • Hospital del Mar
    • Barcelona, Cataluña, Spain, 08041
      • Hospital de La Santa Creu I Sant Pau
  • Comunidad Valenciana
    • Alicante, Comunidad Valenciana, Spain, 03010
      • Hospital General Universitario de Alicante
• Switzerland
  • Lausanne, Switzerland, 1011
    • Centre Hospitalier Universitaire Vaudois
• Ukraine
  • Chernivtsi, Ukraine, 58002
    • Chernivtsi Regional Skin and Venereal Dispensary
  • Dnipro, Ukraine, 49074
    • Regional Skin and Venereal Dispensary
  • Ivano-Frankivsk, Ukraine, 76018
    • Ivano-Frankivsk Regional Skin and Venereal Dispensary
  • Kyiv, Ukraine, 02000
    • Medical clinic Blagomed
  • Uzhhorod, Ukraine, 88000
    • Asclepius
  • Zaporizhzhia, Ukraine, 69000
    • Military Hospital, Military Unit A3309 of the Military Medical Clinical Center
• United Kingdom
  • Dundee, United Kingdom, DD1 9SY
    • Ninewells Hospital
  • London, United Kingdom, E11 1NR
    • Whipps Cross University Hospital
  • Southampton, United Kingdom, SO16 6YD
    • Southampton General Hospital
• United States
  • California
    • Fountain Valley, California, United States, 92708
      • First OC Dermatology
    • Santa Monica, California, United States, 90404
      • Clinical Science Institute
  • Georgia
    • Alpharetta, Georgia, United States, 30022
      • Hamilton Research, LLC
  • Illinois
    • Springfield, Illinois, United States, 62702
      • Southern Illinois University School of Medicine
    • West Dundee, Illinois, United States, 60118
      • Dundee Dermatology
  • Indiana
    • Clarksville, Indiana, United States, 47129
      • DS Research
  • Kansas
    • Overland Park, Kansas, United States, 66215
      • Epiphany Dermatology of Kansas, LLC
  • Kentucky
    • Louisville, Kentucky, United States, 40217
      • Skin Sciences Pllc
    • Louisville, Kentucky, United States, 40241
      • Scott Health Services LLC
  • Michigan
    • Clarkston, Michigan, United States, 48346
      • Clarkston Skin Research
  • Nevada
    • Henderson, Nevada, United States, 89052
      • J Woodson Dermatology and Associates
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai Hospital
    • Stony Brook, New York, United States, 11790
      • DermResearch Center of New York Inc
  • Tennessee
    • Nashville, Tennessee, United States, 37215
      • Tennessee Clinical Research Center
  • Texas
    • Dallas, Texas, United States, 75231
      • Modern Research Associates
  • Washington
    • Spokane, Washington, United States, 99202
      • Premier Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject has provided informed consent prior to initiation of any study specific activities/procedures.
• Age greater than or equal to 18 to less than or equal to 75 years at screening.
• Clinical diagnosis of chronic AD (also known as atopic eczema) for at least 2 years prior to screening and has confirmed AD (Hanifin and Rajka criteria for AD (Hanifin and Rajka, 1980).
• AD that affects greater than or equal to' 10% body surface area as assessed by EASI at screening and on day 1.
• An IGA score of greater than or equal to 3 at screening and on day 1.
• An EASI score of greater than or equal to 16 at screening and on day 1.
• Subject discontinued treatment with TCS, topical calcineurin inhibitors (TCI), and prescription moisturizers containing TCS or topical calcineurin inhibitors (TCI) for at least the 7 days immediately prior to the first dose of investigational product

• Documented recent history (within 12 months before the screening visit) of inadequate response totreatment with topical TCS or subjects for whom topical treatments are otherwise medically inadvisable (ie, because of important side effects or safety risks).

  • Inadequate response is defined as failure to achieve and maintain remission or a low disease activity state (comparable to IGA 0 = clear to IGA 2 = mild) despite treatment with a daily regimen of TCS of medium or higher potency (with or without TCI as appropriate).

Exclusion Criteria:

• Active dermatologic conditions, which might confound the diagnosis of AD or would interfere with the assessment of treatment, such as scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, allergic contact dermatitis, or irritant contact dermatitis.
• History of a clinically significant infection within 28 days prior to day 1 that, in the opinion of the investigator or medical monitor, might compromise the safety of the subject in the study, interfere with evaluation of the investigational product, or reduce the subject's ability to participate in the study. Clinically significant infections are defined as either of the following: 1) a systemic infection; or 2) a serious skin infection requiring parenteral antibiotic, antiviral, or antifungal medication.
• Diagnosis of a helminth parasitic infection within 6 months prior to screening that had not been treated with or had failed to respond to standard of care therapy.
• Documented medical history of chronic alcohol or drug abuse within 12 months prior to screening.
• History of anaphylaxis following any biologic therapy.
• Evidence of active liver disease at screening, including jaundice or aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase greater than twice the upper limit of normal (ULN).

• Subjects who, in the opinion of the investigator, have evidence of active tuberculosis (TB), either treated or untreated, or a positive QuantiFERON-tuberculosis Gold (QFT-G) test for TB during screening. Subjects with an indeterminate QFT-G may be enrolled if they have ALL of the following:

  • No symptoms of TB: productive, prolonged cough (> 3 weeks); coughing up blood; fever; night sweats; unexplained appetite loss; unintentional weight loss
  • No evidence of active TB on chest radiograph within 3 months prior to the first dose of investigational product. Note: Chest radiograph is not part of screening procedure and will be the responsibility
• Positive hepatitis B surface antigen or hepatitis C antibody serology. Subjects with a history of hepatitis B vaccination without a history of hepatitis B are allowed to enroll in the study.
• Positive human immunodeficiency virus (HIV) test at screening or the subject is taking antiretroviral medications, as determined by medical history, prior medications, and/or the subject's verbal report.
• Other Medical Conditions>
• History of malignancy, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 12 months prior to screening or other malignancies treated with apparent success with curative therapy ≥ 5 years prior to screening.
• History or evidence of severe depression, schizophrenia, previous suicide attempts, or suicidal ideation.

Prior/Concomitant Therapy:

• Subjects who are unwilling to abstain from the use of TCS, TCI, and prescription moisturizers (those that contain TCS and TCI) from screening through week 16 (applies only to Part A subjects)
• Subjects who have had side effects of topical medications including intolerance to treatment, hypersensitivity reactions, significant skin atrophy, or systemic effects as assessed by the investigator or by the subject's treating physician (applies only to Part B subjects)
• More than or equal to 30% of the total lesional surface is located on areas of thin skin that cannot be safely treated with medium or higher potency TCS (eg, face, neck, intertriginous areas, areas of skin atrophy) (applies only to Part B subjects)
• Receipt of any approved biologic agent (eg, dupilumab) within 4 months or 5 elimination half-lives (whichever is longer) prior to screening
• Have used immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon (IFN)-gamma, Janus kinase inhibitors, azathioprine, methotrexate) within 4 weeks prior to screening, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 4 weeks of study treatment.
• Have had phototherapy for AD in the 2 months prior to day 1, and subjects unwilling to avoid phototherapy during the first 16 weeks of the study
• If on allergen-specific immunotherapy, subjects must be on a maintenance dose and schedule for ≥ 28 days prior to screening. Allergen-specific immunotherapy is defined as SC immunotherapy to aeroallergens and/o venom (Hymenoptera) as well as sublingual immunotherapy to aeroallergens
• Vaccination with a live or attenuated vaccine within 28 days prior to day 1. Receipt of inactive/killed vaccinations (eg, inactive influenza) is allowed. Note that receipt of the Th2 cytokine inhibitor suplatast within 15 days prior to randomization and during the study is not allowed.
• Major surgery within 8 weeks prior to screening or planned inpatient surgery or hospitalization during the study period
• Currently receiving treatment in another investigational device or drug study, or less than 6 months since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.

Other Exclusions:

• Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product. (Females of childbearing potential should only be enrolled in the study after a negative highly sensitive serum pregnancy test).
• Female subjects of childbearing potential who are sexually active with unsterilized male partners unwilling to use 1 highly effective method of contraception during treatment and for an additional 16 weeks after the last dose of investigational product. Cessation of contraception after this point must be discussed with a responsible physician. Females of childbearing potential are defined as those who are not surgically sterile (ie, had bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). A highly effective method of contraception is defined as one that resulted in a low failure rate (ie, < 1% per year) when used consistently and correctly.
• Subject has known sensitivity to any of the products or components to be administered during dosing.
• History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Part A: Placebo; Matching placebo administered via SC injection Q2W for a maximum of 52 weeks. Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose.	Other: Placebo; Placebo solution for injection
Experimental: Part A: Tezepelumab 210 mg; Tezepelumab 210 mg administered via SC injection once every 4 weeks (Q4W) from Week 4 for a maximum of 52 weeks. All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive a placebo at Week 2 to maintain blinding. Participants defined as non-responders (those who do not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose.	Drug: Tezepelumab; Solution for injection; Other Names: AMG157
Experimental: Part A: Tezepelumab 280 mg; Tezepelumab 280 mg administered via SC injection Q2W from Week 2 for a maximum of 52 weeks. All participants randomized to tezepelumab will receive 420 mg SC injection as their first dose. Participants will then receive their randomized dose of 280 mg Q2W from Week 2. Participants defined as non-responders (those who did not achieve at least 50% improvement in EASI at Week 16 compared to baseline) will switch to receive tezepelumab 420 mg SC injection Q2W for the remainder of the study beginning with the Week 18 dose.	Drug: Tezepelumab; Solution for injection; Other Names: AMG157
Experimental: Part A: Tezepelumab 420 mg; Tezepelumab 420 mg administered via SC injection Q2W for a maximum of 52 weeks.	Drug: Tezepelumab; Solution for injection; Other Names: AMG157
Experimental: Part B: Placebo and Topical Corticosteroids Regimen; Matching placebo administered via SC injection Q2W with topical corticosteroids (TCS) for a maximum of 52 weeks.	Drug: Tezepelumab; Solution for injection; Other Names: AMG157
Experimental: Part B: Tezepelumab 420 mg and Topical Corticosteroids Regimen; Tezepelumab 420 mg administered via SC injection Q2W with TCS for a maximum of 52 weeks.	Drug: Tezepelumab; Solution for injection; Other Names: AMG157

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) (IGA 0/1) at Week 16	The IGA allows investigators to assess overall disease severity at 1 given time point and consists of a 6-point severity scale from clear to severe disease; 0 = clear; 1 = almost clear; 2 = mild disease; 3 = moderate disease; 4 = severe disease; 5 = very severe disease The IGA uses clinical characteristics of erythema, infiltration, papulation, oozing, and crusting as guidelines for the overall severity assessment (Breuer et al, 2004). Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.	Week 16
Number of Participants Who Experienced a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16	The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration/papulation, excoriation, and lichenification). A reduction in the EASI score indicates an improvement in severity. Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.	Baseline and Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Experienced a 50% or 90% Reduction From Baseline in Eczema Area and Severity Index (EASI 50/90) at Week 16	The EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on key acute and chronic signs of inflammation (ie, erythema, induration/papulation, excoriation, and lichenification). A reduction in the EASI score indicates an improvement in severity. Participants who took rescue medication between Day 29 to Week 16 were considered non-responders.	Baseline and Week 16
Time to Achievement of 50%, 75% or 90% Reduction From Day 1 in Eczema Area and Severity Index (EASI 50/75/90)		Day 1 up to End of Study Visit (Week 70)
Change From Baseline in Scoring of Atopic Dermatitis (SCORAD) at Week 16	The SCORAD is a clinical tool for assessing the severity (ie, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with subjective symptoms (Kunz et al, 1997). The total score ranges from 0 to 103, with higher values indicating more severe disease. A negative change from baseline indicates an improvement in severity of disease.	Baseline and Week 16
Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16	Pruritus was assessed using an NRS (0-10) with 0 = no itch and 10 = worst imaginable itch. A negative change from baseline indicates an improvement in symptoms.	Baseline and Week 16
Serum Trough Concentrations of Tezepelumab After Q2W or Q4W Administration	Switchers were included up to Week 16 and were then excluded from the analysis after switching. All Tezepelumab participants received 420 mg of Tezepelumab on Day 1.	Pre-dose on Day 1, Week 2, 4, 12, 16, 24, 32, 40, 48, 50, 52, 58 and 70
Serum Trough Concentrations of Tezepelumab After Switching to 420 mg Q2W Administration After Week 16		Pre-dose on Week 24, 32, 40, 48, 50, 52, 58 and 70

Collaborators and Investigators

• Sponsor: Amgen
• Collaborators: AstraZeneca

Publications and helpful links

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2019
• Primary Completion (Actual): May 12, 2020
• Study Completion (Actual): December 22, 2020

Study Registration Dates

• First Submitted: January 10, 2019
• First Submitted That Met QC Criteria: January 17, 2019
• First Posted (Actual): January 18, 2019

Study Record Updates

• Last Update Posted (Actual): March 10, 2022
• Last Update Submitted That Met QC Criteria: March 9, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: skin; eczema; dermatology; inflammation; Atopic Dermatitis; dermatitis; tezepelumab; moderate dermatitis; severe dermatitis
• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Eczema; Dermatitis, Atopic
• Other Study ID Numbers: 20170755; 2018-001997-52 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
• IPD Sharing Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• IPD Sharing Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No